Stryker's (SYK) Spine Guidance 5 Software featuring Copilot receives 510(k) clearance from FDA
Get Alerts SYK Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.2%
Revenue Growth %: +9.3%
Join SI Premium – FREE
Stryker (NYSE: SYK), a global leader in medical technologies, today announced that its Q Guidance System with Spine Guidance 5 Software featuring Copilot received 510(k) clearance from the U.S. Food and Drug Administration. This first-to-market technology seamlessly integrates smart-powered* instruments into Stryker's growing ecosystem.
Spine Guidance Software with Copilot's breakthrough technology was built to provide multiple feedback modalities for supporting bone resection, pedicle preparation and screw delivery to help maximize a surgeon's effectiveness and enhance patient outcomes. Stryker engaged over 850 orthopaedic spine surgeons and neurosurgeons to develop this technology.
"This project is a prime example of our mission in action," said
Smart Zones for bone resection provide auditory and sensory feedback when surgeons approach the planned boundaries of anatomical alert zones with the high-speed drill. To complement Smart Zones, the Copilot Smart Driver** stops automatically when it reaches the planned depth, supporting surgeon precision during pedicle preparation and screw placement. The automatic depth stop feature is proprietary technology that unlocks only when using a Stryker implant.
"Spine Guidance Software with Copilot is just the beginning of our development pipeline," said
The first clinical cases using Spine Guidance Software with Copilot will begin in September, with a full commercial launch expected later this fall. For more information on Spine Guidance Software with Copilot please visit https://www.stryker.com/us/en/nse/products/spine-guidance-software-copilot.html.
*Smart features enabled by the Q Guidance System with Spine Guidance 5 Software.
**SPINE-COP-BROC-1169302
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MacroGenics to receive $24.5M milestone from Sanofi on FDA approval
- Murphy Oil announces oil discovery offshore Côte d'Ivoire
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
Create E-mail Alert Related Categories
Corporate News, FDARelated Entities
Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share